CANCIDAS Side Effects

7005700-5 | Dilatation Intrahepatic Duct Acquired, Hepatotoxicity, Liver Function Test Abnormal, Venoocclusive Disease
on Sep 17, 2010 Female patient from UNITED KINGDOM , 19 years of age, was diagnosed with pain (What is pain?) and was treated with Cancidas (View Usage). Patient experienced the following unwanted or unexpected effects: dilatation intrahepatic duct acquired, hepatotoxicity, liver function test abnormal, venoocclusive disease. Cancidas dosage: . During the same period patient was treated with ACYCLOVIR (View Acyclovir Review and Acyclovir Label ), ALLOPURINOL (View Allopurinol Review and Allopurinol Label ), CHLORPHENIRAMINE MALEATE (View Chlorpheniramine Maleate Review and Chlorpheniramine Maleate Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), ETOPOSIDE (View Etoposide Review and Etoposide Label ), KETAMINE HYDROCHLORIDE (View Ketamine Hydrochloride Review and Ketamine Hydrochloride Label ), MORPHINE (View Morphine Review and Morphine Label ), NORETHINDRONE (View Norethindrone Review and Norethindrone Label ).

7001886-7 | Culture Positive
Patient was taking Cancidas (View Usage). Patient had the following side effects: culture positive on Sep 09, 2010 from UNITED STATES Additional patient health information: Male patient , 53 years of age, weighting 352.7 lb, was diagnosed with septic shock, bacterial infection (What is bacterial infection?) and. Cancidas dosage: . During the same period patient was treated with TYLENOL (View Tylenol Review and Tylenol Label ), PROVENTIL (View Proventil Review and Proventil Label ), PEPCID (View Pepcid Review and Pepcid Label ), INSULIN (View Insulin Review and Insulin Label ), VERSED (View Versed Review and Versed Label ). Patient was hospitalized and became disabled.

6981113-7 | Dilatation Intrahepatic Duct Acquired, Hepatotoxicity, Liver Function Test Abnormal, Venoocclusive Disease
Adverse event was reported on Sep 09, 2010 by a Female patient taking Cancidas (View Usage) (Dosage: ) was diagnosed with pain (What is pain?) and. Location: UNITED KINGDOM , 19 years of age, After Cancidas was administered, patient had the following side effects: dilatation intrahepatic duct acquired, hepatotoxicity, liver function test abnormal, venoocclusive disease. During the same period patient was treated with ACYCLOVIR (View Acyclovir Review and Acyclovir Label ), ALLOPURINOL (View Allopurinol Review and Allopurinol Label ), CHLORPHENIRAMINE MALEATE (View Chlorpheniramine Maleate Review and Chlorpheniramine Maleate Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), ETOPOSIDE (View Etoposide Review and Etoposide Label ), KETAMINE HYDROCHLORIDE (View Ketamine Hydrochloride Review and Ketamine Hydrochloride Label ), MORPHINE (View Morphine Review and Morphine Label ), NORETHINDRONE (View Norethindrone Review and Norethindrone Label ).

6977556-8 | Convulsion
on Sep 06, 2010 Female patient from FRANCE , 15 years of age, was treated with Cancidas (View Usage). Patient experienced the following unwanted or unexpected effects: convulsion. Cancidas dosage: . During the same period patient was treated with PRIMAXIN (View Primaxin Review and Primaxin Label ), ACUPAN (View Acupan Review and Acupan Label ), VANCOMYCIN HYDROCHLORIDE (View Vancomycin Hydrochloride Review and Vancomycin Hydrochloride Label ). Patient was hospitalized.


6977092-9 | Alanine Aminotransferase Increased, Blood Alkaline Phosphatase Increased, Blood Bilirubin Increased, Dilatation Intrahepatic Duct Acquired, Hepatotoxicity, Liver Function Test Abnormal, Venoocclusive Disease
on Sep 06, 2010 Female patient from UNITED KINGDOM , 19 years of age, was diagnosed with pain (What is pain?) and was treated with Cancidas (View Usage). Patient had the following side effects: alanine aminotransferase increased, blood alkaline phosphatase increased, blood bilirubin increased, dilatation intrahepatic duct acquired, hepatotoxicity, liver function test abnormal, venoocclusive disease. Cancidas dosage: . During the same period patient was treated with ACYCLOVIR (View Acyclovir Review and Acyclovir Label ), ALLOPURINOL (View Allopurinol Review and Allopurinol Label ), CHLORPHENIRAMINE MALEATE (View Chlorpheniramine Maleate Review and Chlorpheniramine Maleate Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), ETOPOSIDE (View Etoposide Review and Etoposide Label ), KETAMINE HYDROCHLORIDE (View Ketamine Hydrochloride Review and Ketamine Hydrochloride Label ), MORPHINE (View Morphine Review and Morphine Label ), NORETHINDRONE (View Norethindrone Review and Norethindrone Label ).

6971797-1 | Hepatitis, Hyperbilirubinaemia
Patient was taking Cancidas (View Usage). After Cancidas was administered, patient had the following side effects: hepatitis (What is hepatitis?), hyperbilirubinaemia on Sep 07, 2010 from SPAIN Additional patient health information: Female patient , 34 years of age, was diagnosed with neutropenia, bone marrow transplant (What is bone marrow transplant?), respiratory tract infection and. Cancidas dosage: . During the same period patient was treated with ACYCLOVIR (View Acyclovir Review and Acyclovir Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), AMIKACIN (View Amikacin Review and Amikacin Label ), MEROPENEM (View Meropenem Review and Meropenem Label ), ZYVOX (View Zyvox Review and Zyvox Label ).

6968754-8 | Dilatation Intrahepatic Duct Acquired, Hepatotoxicity, Liver Function Test Abnormal, Venoocclusive Disease
Adverse event was reported on Sep 01, 2010 by a Female patient taking Cancidas (View Usage) (Dosage: ) was diagnosed with pain (What is pain?) and. Location: UNITED KINGDOM , 19 years of age, Patient experienced the following unwanted or unexpected effects: dilatation intrahepatic duct acquired, hepatotoxicity, liver function test abnormal, venoocclusive disease. During the same period patient was treated with ACYCLOVIR (View Acyclovir Review and Acyclovir Label ), ALLOPURINOL (View Allopurinol Review and Allopurinol Label ), CHLORPHENIRAMINE MALEATE (View Chlorpheniramine Maleate Review and Chlorpheniramine Maleate Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), ETOPOSIDE (View Etoposide Review and Etoposide Label ), KETAMINE HYDROCHLORIDE (View Ketamine Hydrochloride Review and Ketamine Hydrochloride Label ), MORPHINE (View Morphine Review and Morphine Label ), NORETHINDRONE (View Norethindrone Review and Norethindrone Label ).

6960514-7 | Abdominal Wound Dehiscence, Arterial Disorder, Biliary Tract Infection, Incisional Hernia, White Blood Cell Count Increased
on Aug 19, 2010 Male patient from GERMANY , 51 years of age, was diagnosed with antifungal prophylaxis and was treated with Cancidas (View Usage). Patient had the following side effects: abdominal wound dehiscence, arterial disorder, biliary tract infection, incisional hernia, white blood cell count increased. Cancidas dosage: 70 Mg/daily/iv, 50 Mg/daily/iv. Patient was hospitalized.

6956866-4 | Stevens-johnson Syndrome
on Aug 24, 2010 Male patient from FRANCE , 58 years of age, was treated with Cancidas (View Usage). After Cancidas was administered, patient had the following side effects: stevens-johnson syndrome. Cancidas dosage: . During the same period patient was treated with VANCOMYCIN (View Vancomycin Review and Vancomycin Label ), ESOMEPRAZOLE MAGNESIUM (View Esomeprazole Magnesium Review and Esomeprazole Magnesium Label ), ACETAMINOPHEN (View Acetaminophen Review and Acetaminophen Label ), CEFTRIAXONE SODIUM (View Ceftriaxone Sodium Review and Ceftriaxone Sodium Label ), PIPERACILLIN AND TAZOBACTAM (View Piperacillin And Tazobactam Review and Piperacillin And Tazobactam Label ), FLUCONAZOLE (View Fluconazole Review and Fluconazole Label ), METHYLPREDNISOLONE SODIUM SUCCINATE (View Methylprednisolone Sodium Succinate Review and Methylprednisolone Sodium Succinate Label ). Patient was hospitalized.

6934718-3 | Convulsion
Patient was taking Cancidas (View Usage). Patient experienced the following unwanted or unexpected effects: convulsion on Aug 13, 2010 from FRANCE Additional patient health information: Female patient , 38 years of age, was diagnosed with epilepsy (What is epilepsy?) and. Cancidas dosage: . During the same period patient was treated with VALPROATE SODIUM (View Valproate Sodium Review and Valproate Sodium Label ), FLUOXETINE (View Fluoxetine Review and Fluoxetine Label ), CEFTAZIDIME (View Ceftazidime Review and Ceftazidime Label ), MIDAZOLAM (View Midazolam Review and Midazolam Label ), SUFENTANIL (View Sufentanil Review and Sufentanil Label ), ACETAMINOPHEN (View Acetaminophen Review and Acetaminophen Label ), NOREPINEPHRINE (View Norepinephrine Review and Norepinephrine Label ). Patient was hospitalized.

6934116-2 | Bronchopulmonary Aspergillosis
Adverse event was reported on Aug 05, 2010 by a Female patient taking Cancidas (View Usage) (Dosage: ) was diagnosed with prophylaxis, acute lymphocytic leukaemia and. Location: FRANCE , 61 years of age, Patient had the following side effects: bronchopulmonary aspergillosis. Patient was hospitalized.

6934114-9 | Bronchopulmonary Aspergillosis
on Aug 05, 2010 Female patient from FRANCE , 58 years of age, was diagnosed with prophylaxis, acute myeloid leukaemia and was treated with Cancidas (View Usage). After Cancidas was administered, patient had the following side effects: bronchopulmonary aspergillosis. Cancidas dosage: . Patient was hospitalized.

6934112-5 | Bronchopulmonary Aspergillosis
on Aug 05, 2010 Female patient from FRANCE , 43 years of age, was diagnosed with prophylaxis, congenital aplastic anaemia and was treated with Cancidas (View Usage). Patient experienced the following unwanted or unexpected effects: bronchopulmonary aspergillosis. Cancidas dosage: . Patient was hospitalized.

6934108-3 | Bronchopulmonary Aspergillosis
Patient was taking Cancidas (View Usage). Patient had the following side effects: bronchopulmonary aspergillosis on Aug 05, 2010 from FRANCE Additional patient health information: Female patient , 60 years of age, was diagnosed with prophylaxis, acute myeloid leukaemia and. Cancidas dosage: . Patient was hospitalized.

6934103-4 | Bronchopulmonary Aspergillosis
Adverse event was reported on Aug 05, 2010 by a Female patient taking Cancidas (View Usage) (Dosage: ) was diagnosed with prophylaxis, acute myeloid leukaemia and. Location: FRANCE , 48 years of age, After Cancidas was administered, patient had the following side effects: bronchopulmonary aspergillosis. Patient was hospitalized.

6934095-8 | Bronchopulmonary Aspergillosis
on Aug 05, 2010 Female patient from FRANCE , 21 years of age, was diagnosed with prophylaxis, aplastic anaemia and was treated with Cancidas (View Usage). Patient experienced the following unwanted or unexpected effects: bronchopulmonary aspergillosis. Cancidas dosage: . Patient was hospitalized.

6923365-5 | Bronchopulmonary Aspergillosis
on Aug 02, 2010 Male patient from CHINA , 53 years of age, was diagnosed with aspergillosis and was treated with Cancidas (View Usage). Patient had the following side effects: bronchopulmonary aspergillosis. Cancidas dosage: . During the same period patient was treated with AMPHOTERICIN B (View Amphotericin B Review and Amphotericin B Label ).

6914634-3 | Hyperkalaemia
Patient was taking Cancidas (View Usage). After Cancidas was administered, patient had the following side effects: hyperkalaemia on Aug 03, 2010 from BELGIUM Additional patient health information: Male patient , 66 years of age, weighting 145.5 lb, was diagnosed with infection prophylaxis and. Cancidas dosage: . Patient was hospitalized.

6878478-3 | Delirium
Adverse event was reported on Jul 21, 2010 by a Male patient taking Cancidas (View Usage) (Dosage: ) was diagnosed with bronchitis (What is bronchitis?), prophylaxis and. Location: SWITZERLAND , 60 years of age, Patient experienced the following unwanted or unexpected effects: delirium. During the same period patient was treated with LEXOTANIL (View Lexotanil Review and Lexotanil Label ), VANCOMYCIN (View Vancomycin Review and Vancomycin Label ), PREDNISONE (View Prednisone Review and Prednisone Label ), TACROLIMUS (View Tacrolimus Review and Tacrolimus Label ), HEPARIN (View Heparin Review and Heparin Label ), ASPIRIN (View Aspirin Review and Aspirin Label ), METOCLOPRAMIDE (View Metoclopramide Review and Metoclopramide Label ), ALBUTEROL (View Albuterol Review and Albuterol Label ).

6865996-7 | Arterial Disorder, Arterial Occlusive Disease, Hypoperfusion, Platelet Count Decreased, Prothrombin Time Prolonged
on Jun 06, 2010 Male patient from GERMANY , 51 years of age, was treated with Cancidas (View Usage). Patient had the following side effects: arterial disorder, arterial occlusive disease, hypoperfusion, platelet count decreased, prothrombin time prolonged. Cancidas dosage: .

6865995-5 | Arterial Disorder, Arterial Occlusive Disease, Hypoperfusion, Platelet Count Decreased, Prothrombin Time Prolonged
on Jun 22, 2010 Male patient from GERMANY , 51 years of age, was treated with Cancidas (View Usage). After Cancidas was administered, patient had the following side effects: arterial disorder, arterial occlusive disease, hypoperfusion, platelet count decreased, prothrombin time prolonged. Cancidas dosage: .

6860812-1 | Acute Graft Versus Host Disease In Skin, Adenovirus Infection, Anuria, Blood Lactate Dehydrogenase Increased, Circulatory Collapse, Multi-organ Failure, Pyrexia, Renal Hypertrophy, Respiratory Failure
Patient was taking Cancidas (View Usage). Patient experienced the following unwanted or unexpected effects: acute graft versus host disease in skin, adenovirus infection, anuria, blood lactate dehydrogenase increased, circulatory collapse, multi-organ failure, pyrexia, renal hypertrophy, respiratory failure on Jul 10, 2010 from GERMANY Additional patient health information: Female patient , 23 years of age, was diagnosed with aspergillus test positive, lung infiltration, immunosuppression, pneumonia (What is pneumonia?), adenovirus infection and. Cancidas dosage: . During the same period patient was treated with METHYLPREDNISOLONE (View Methylprednisolone Review and Methylprednisolone Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), VORICONAZOLE (View Voriconazole Review and Voriconazole Label ), IMIPENEM (View Imipenem Review and Imipenem Label ), TEICOPLANIN (View Teicoplanin Review and Teicoplanin Label ), CIDOFOVIR (View Cidofovir Review and Cidofovir Label ), MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ).

6858468-7 | Aspergillosis, Bacterial Infection
Adverse event was reported on Feb 03, 2010 by a Male patient taking Cancidas (View Usage) (Dosage: ) was diagnosed with aspergillosis, prophylaxis and. Location: BELGIUM , 69 years of age, weighting 220.5 lb, Patient had the following side effects: aspergillosis, bacterial infection (What is bacterial infection?). During the same period patient was treated with AMPHOTERICIN B AND L (ALPHA) DIMYRISTOYLPHOSPHATIDYLCHOLINE AND L (ALP (View Amphotericin B And L-(alpha)-dimyristoylphosphatidylcholine And L-(alp Review and Amphotericin B And L-(alpha)-dimyristoylphosphatidylcholine And L-(alp Label ), VORICONAZOLE (View Voriconazole Review and Voriconazole Label ).

6831757-8 | Arterial Disorder, Arterial Occlusive Disease, Hypoperfusion, Platelet Count Decreased, Prothrombin Time Prolonged
on Jun 22, 2010 Male patient from GERMANY , 51 years of age, was treated with Cancidas (View Usage). After Cancidas was administered, patient had the following side effects: arterial disorder, arterial occlusive disease, hypoperfusion, platelet count decreased, prothrombin time prolonged. Cancidas dosage: .

6745062-1 | Renal Failure
on May 25, 2010 Male patient from FRANCE , 16 years of age, was diagnosed with aspergillosis and was treated with Cancidas (View Usage). Patient experienced the following unwanted or unexpected effects: renal failure. Cancidas dosage: . During the same period patient was treated with TOBRADEX (View Tobradex Review and Tobradex Label ), POLARAMIDE (View Polaramide Review and Polaramide Label ), VOGALENE (View Vogalene Review and Vogalene Label ), ZOPHREN (View Zophren Review and Zophren Label ), SABRIL (View Sabril Review and Sabril Label ). Patient was hospitalized.

6732413-7 | Diabetes Insipidus
Patient was taking Cancidas (View Usage). Patient had the following side effects: diabetes insipidus (What is diabetes insipidus?) on May 10, 2010 from AUSTRALIA Additional patient health information: Female patient , 53 years of age, weighting 264.6 lb, was diagnosed with fungaemia and. Cancidas dosage: . During the same period patient was treated with ACETAMINOPHEN (View Acetaminophen Review and Acetaminophen Label ), MEROPENEM (View Meropenem Review and Meropenem Label ), THIAMINE (View Thiamine Review and Thiamine Label ), CERNEVIT 12 (View Cernevit-12 Review and Cernevit-12 Label ), PHYTONADIONE (View Phytonadione Review and Phytonadione Label ), ESOMEPRAZOLE (View Esomeprazole Review and Esomeprazole Label ), ALBUTEROL (View Albuterol Review and Albuterol Label ). Patient was hospitalized.

6728019-6 | Toxic Epidermal Necrolysis
Adverse event was reported on May 12, 2010 by a Female patient taking Cancidas (View Usage) (Dosage: ) was diagnosed with fungal infection (What is fungal infection?), enterococcal infection, enterobacter infection and. Location: UNITED STATES , 40 years of age, weighting 229.3 lb, After Cancidas was administered, patient had the following side effects: toxic epidermal necrolysis. During the same period patient was treated with ZOSYN (View Zosyn Review and Zosyn Label ).

6722734-6 | Stevens-johnson Syndrome
on May 07, 2010 Female patient from FRANCE , 47 years of age, was diagnosed with enterobacter infection, bacteroides infection and was treated with Cancidas (View Usage). Patient experienced the following unwanted or unexpected effects: stevens-johnson syndrome. Cancidas dosage: . During the same period patient was treated with AUGMENTIN '125' (View Augmentin '125' Review and Augmentin '125' Label ), OMEPRAZOLE (View Omeprazole Review and Omeprazole Label ). Patient was hospitalized.

6717840-6 | Cytolytic Hepatitis, Hepatitis Cholestatic
on Apr 30, 2010 Female patient from FRANCE , 38 years of age, weighting 149.9 lb, was diagnosed with infection (What is infection?), tuberculosis gastrointestinal and was treated with Cancidas (View Usage). Patient had the following side effects: cytolytic hepatitis, hepatitis cholestatic. Cancidas dosage: . During the same period patient was treated with ISONIAZID (View Isoniazid Review and Isoniazid Label ), RIFAMPIN (View Rifampin Review and Rifampin Label ), ETHAMBUTOL HYDROCHLORIDE (View Ethambutol Hydrochloride Review and Ethambutol Hydrochloride Label ), CILASTATIN SODIUM AND IMIPENEM (View Cilastatin Sodium And Imipenem Review and Cilastatin Sodium And Imipenem Label ), VANCOMYCIN (View Vancomycin Review and Vancomycin Label ), ESOMEPRAZOLE MAGNESIUM (View Esomeprazole Magnesium Review and Esomeprazole Magnesium Label ). Patient was hospitalized.

6710617-7 | Toxic Epidermal Necrolysis
Patient was taking Cancidas (View Usage). After Cancidas was administered, patient had the following side effects: toxic epidermal necrolysis on Apr 21, 2010 from TAIWAN, PROVINCE OF CHINA Additional patient health information: Male patient , 86 years of age, weighting 160.9 lb, was diagnosed with systemic candida, sepsis (What is sepsis?) and. Cancidas dosage: . During the same period patient was treated with CILASTATIN SODIUM AND IMIPENEM (View Cilastatin Sodium And Imipenem Review and Cilastatin Sodium And Imipenem Label ), TEICOPLANIN (View Teicoplanin Review and Teicoplanin Label ), SPIRONOLACTONE (View Spironolactone Review and Spironolactone Label ), PANTOPRAZOLE (View Pantoprazole Review and Pantoprazole Label ), METOCLOPRAMIDE (View Metoclopramide Review and Metoclopramide Label ).

6708694-2 | Duodenal Ulcer, Gastric Ulcer, Gastrointestinal Haemorrhage
Adverse event was reported on Apr 26, 2010 by a Female patient taking Cancidas (View Usage) (Dosage: ) was diagnosed with candidiasis, b precursor type acute leukaemia and. Location: IRELAND , child 3 years of age, Patient experienced the following unwanted or unexpected effects: duodenal ulcer, gastric ulcer, gastrointestinal haemorrhage. During the same period patient was treated with DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ), VINCRISTINE SULFATE (View Vincristine Sulfate Review and Vincristine Sulfate Label ), PEGASPARGASE (View Pegaspargase Review and Pegaspargase Label ), METHOTREXATE SODIUM (View Methotrexate Sodium Review and Methotrexate Sodium Label ). Patient was hospitalized.

6705289-1 | Blood Creatinine Increased, Blood Urea Increased, Depressed Level Of Consciousness, Sepsis, Shock, Toxic Epidermal Necrolysis
on Apr 21, 2010 Male patient from TAIWAN, PROVINCE OF CHINA , 86 years of age, weighting 160.9 lb, was diagnosed with systemic candida, sepsis (What is sepsis?) and was treated with Cancidas (View Usage). Patient had the following side effects: blood creatinine increased, blood urea increased, depressed level of consciousness, sepsis (What is sepsis?), shock, toxic epidermal necrolysis. Cancidas dosage: . During the same period patient was treated with CILASTATIN SODIUM AND IMIPENEM (View Cilastatin Sodium And Imipenem Review and Cilastatin Sodium And Imipenem Label ), TEICOPLANIN (View Teicoplanin Review and Teicoplanin Label ), SPIRONOLACTONE (View Spironolactone Review and Spironolactone Label ), PANTOPRAZOLE (View Pantoprazole Review and Pantoprazole Label ), METOCLOPRAMIDE (View Metoclopramide Review and Metoclopramide Label ), DIGOXIN (View Digoxin Review and Digoxin Label ), CYPROHEPTADINE HYDROCHLORIDE (View Cyproheptadine Hydrochloride Review and Cyproheptadine Hydrochloride Label ), BUDESONIDE (View Budesonide Review and Budesonide Label ).

6693270-0 | Stevens-johnson Syndrome
on Apr 19, 2010 Female patient from FRANCE , 47 years of age, was diagnosed with enterobacter infection, bacteroides infection and was treated with Cancidas (View Usage). After Cancidas was administered, patient had the following side effects: stevens-johnson syndrome. Cancidas dosage: . During the same period patient was treated with AUGMENTIN '125' (View Augmentin '125' Review and Augmentin '125' Label ), OMEPRAZOLE (View Omeprazole Review and Omeprazole Label ), SUFENTANIL CITRATE (View Sufentanil Citrate Review and Sufentanil Citrate Label ), ACUPAN (View Acupan Review and Acupan Label ), HUMALOG (View Humalog Review and Humalog Label ), ATARAX (ALPRAZOLAM) (View Atarax (alprazolam) Review and Atarax (alprazolam) Label ). Patient was hospitalized.

6666150-4 | Fungal Infection
Patient was taking Cancidas (View Usage). Patient experienced the following unwanted or unexpected effects: fungal infection (What is fungal infection?) on Mar 22, 2010 from CANADA Additional patient health information: Female patient , 14 years of age, was diagnosed with antifungal treatment, acute myeloid leukaemia and. Cancidas dosage: . During the same period patient was treated with FLUDARABINE PHOSPHATE (View Fludarabine Phosphate Review and Fludarabine Phosphate Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ). Patient was hospitalized.

6636616-1 | Zygomycosis
Adverse event was reported on Mar 05, 2010 by a Female patient taking Cancidas (View Usage) (Dosage: ) was diagnosed with zygomycosis and. Location: SWITZERLAND , 51 years of age, Patient had the following side effects: zygomycosis. During the same period patient was treated with VORICONAZOLE (View Voriconazole Review and Voriconazole Label ).

6636615-X | Convulsion, Flushing, Gaze Palsy, Rash
on Mar 10, 2010 Female patient from , 52 years of age, was treated with Cancidas (View Usage). After Cancidas was administered, patient had the following side effects: convulsion, flushing, gaze palsy, rash (What is rash?). Cancidas dosage: . During the same period patient was treated with MIDAZOLAM (View Midazolam Review and Midazolam Label ), COLISTIN (View Colistin Review and Colistin Label ).

6600528-X | Chronic Granulomatous Disease, Hepatic Function Abnormal, Multi-organ Failure, Pulmonary Hypertension, Renal Impairment
on Feb 22, 2010 Male patient from UNITED KINGDOM , child 7 years of age, was diagnosed with aspergillosis and was treated with Cancidas (View Usage). Patient experienced the following unwanted or unexpected effects: chronic granulomatous disease, hepatic function abnormal, multi-organ failure, pulmonary hypertension (What is pulmonary hypertension?), renal impairment. Cancidas dosage: . During the same period patient was treated with VORICONAZOLE (View Voriconazole Review and Voriconazole Label ), AMPHOTERICIN B AND CHOLESTEROL AND DISTEAROYLPHOSPHATIDYLGLYCEROL AND (View Amphotericin B And Cholesterol And Distearoylphosphatidylglycerol And Review and Amphotericin B And Cholesterol And Distearoylphosphatidylglycerol And Label ), CHLORAMPHENICOL (View Chloramphenicol Review and Chloramphenicol Label ), DAPTOMYCIN (View Daptomycin Review and Daptomycin Label ), MEROPENEM (View Meropenem Review and Meropenem Label ), CIPROFLOXACIN (View Ciprofloxacin Review and Ciprofloxacin Label ). Patient was hospitalized.

6600521-7 | Angiopathy, Chronic Granulomatous Disease, Multi-organ Failure
Patient was taking Cancidas (View Usage). Patient had the following side effects: angiopathy, chronic granulomatous disease, multi-organ failure on Feb 22, 2010 from UNITED KINGDOM Additional patient health information: Male patient , 14 years of age, was diagnosed with aspergillosis, vasculitis (What is vasculitis?) and. Cancidas dosage: . During the same period patient was treated with VORICONAZOLE (View Voriconazole Review and Voriconazole Label ), INTERFERON GAMMA (View Interferon Gamma Review and Interferon Gamma Label ), METHYLPREDNISOLONE (View Methylprednisolone Review and Methylprednisolone Label ). Patient was hospitalized.

6594253-1 | Chest Pain, Dyspnoea, Hypoxia, Myocardial Infarction, Tachycardia
Adverse event was reported on Feb 16, 2010 by a Male patient taking Cancidas (View Usage) (Dosage: ) was diagnosed with bronchopulmonary aspergillosis allergic and. Location: UNITED KINGDOM , 74 years of age, weighting 132.3 lb, After Cancidas was administered, patient had the following side effects: chest pain (What is chest pain?), dyspnoea, hypoxia, myocardial infarction, tachycardia. During the same period patient was treated with CEFTAZIDIME (View Ceftazidime Review and Ceftazidime Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ), ALBUTEROL (View Albuterol Review and Albuterol Label ). Patient was hospitalized.

6583112-6 | Aspergillosis, Bacterial Infection
on Feb 03, 2010 Male patient from BELGIUM , 69 years of age, weighting 220.5 lb, was diagnosed with aspergillosis, prophylaxis and was treated with Cancidas (View Usage). Patient experienced the following unwanted or unexpected effects: aspergillosis, bacterial infection (What is bacterial infection?). Cancidas dosage: . During the same period patient was treated with AMPHOTERICIN B AND L (ALPHA) DIMYRISTOYLPHOSPHATIDYLCHOLINE AND L (ALP (View Amphotericin B And L-(alpha)-dimyristoylphosphatidylcholine And L-(alp Review and Amphotericin B And L-(alpha)-dimyristoylphosphatidylcholine And L-(alp Label ), VORICONAZOLE (View Voriconazole Review and Voriconazole Label ).

6583100-X | Bacterial Infection, Organ Failure
on Feb 03, 2010 Male patient from BELGIUM , 48 years of age, weighting 174.2 lb, was diagnosed with fungal infection (What is fungal infection?), bacterial infection (What is bacterial infection?), prophylaxis and was treated with Cancidas (View Usage). Patient had the following side effects: bacterial infection (What is bacterial infection?), organ failure. Cancidas dosage: . During the same period patient was treated with AMIKACIN (View Amikacin Review and Amikacin Label ), LINEZOLID (View Linezolid Review and Linezolid Label ), AMPHOTERICIN B AND L (ALPHA) DIMYRISTOYLPHOSPHATIDYLCHOLINE AND L (ALP (View Amphotericin B And L-(alpha)-dimyristoylphosphatidylcholine And L-(alp Review and Amphotericin B And L-(alpha)-dimyristoylphosphatidylcholine And L-(alp Label ), VORICONAZOLE (View Voriconazole Review and Voriconazole Label ).

6580024-9 | Bacterial Infection
Patient was taking Cancidas (View Usage). After Cancidas was administered, patient had the following side effects: bacterial infection (What is bacterial infection?) on Feb 08, 2010 from BELGIUM Additional patient health information: Male patient , 26 years of age, weighting 176.4 lb, was diagnosed with aspergillosis, bacterial infection (What is bacterial infection?) and. Cancidas dosage: . During the same period patient was treated with MEROPENEM (View Meropenem Review and Meropenem Label ), TEICOPLANIN (View Teicoplanin Review and Teicoplanin Label ), VORICONAZOLE (View Voriconazole Review and Voriconazole Label ).

6580018-3 | Condition Aggravated, Fungal Infection, Organ Failure
Adverse event was reported on Feb 05, 2010 by a Female patient taking Cancidas (View Usage) (Dosage: ) was diagnosed with fungal infection (What is fungal infection?), bacterial infection (What is bacterial infection?), prophylaxis and. Location: BELGIUM , 63 years of age, weighting 119.0 lb, Patient experienced the following unwanted or unexpected effects: condition aggravated, fungal infection (What is fungal infection?), organ failure. During the same period patient was treated with MEROPENEM (View Meropenem Review and Meropenem Label ), SULFAMETHOXAZOLE AND TRIMETHOPRIM (View Sulfamethoxazole And Trimethoprim Review and Sulfamethoxazole And Trimethoprim Label ), VANCOMYCIN (View Vancomycin Review and Vancomycin Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), FLUCONAZOLE (View Fluconazole Review and Fluconazole Label ), AMPHOTERICIN B AND L (ALPHA) DIMYRISTOYLPHOSPHATIDYLCHOLINE AND L (ALP (View Amphotericin B And L-(alpha)-dimyristoylphosphatidylcholine And L-(alp Review and Amphotericin B And L-(alpha)-dimyristoylphosphatidylcholine And L-(alp Label ), VORICONAZOLE (View Voriconazole Review and Voriconazole Label ).

6575661-1 | Aspergillosis, Bacterial Infection
on Feb 03, 2010 Male patient from BELGIUM , 69 years of age, weighting 220.5 lb, was diagnosed with aspergillosis, prophylaxis and was treated with Cancidas (View Usage). Patient had the following side effects: aspergillosis, bacterial infection (What is bacterial infection?). Cancidas dosage: . During the same period patient was treated with AMPHOTERICIN B AND L (ALPHA) DIMYRISTOYLPHOSPHATIDYLCHOLINE AND L (ALP (View Amphotericin B And L-(alpha)-dimyristoylphosphatidylcholine And L-(alp Review and Amphotericin B And L-(alpha)-dimyristoylphosphatidylcholine And L-(alp Label ), VORICONAZOLE (View Voriconazole Review and Voriconazole Label ).

6575660-X | Bacterial Infection, Organ Failure
on Feb 03, 2010 Male patient from BELGIUM , 48 years of age, weighting 174.2 lb, was diagnosed with fungal infection (What is fungal infection?), bacterial infection (What is bacterial infection?), prophylaxis and was treated with Cancidas (View Usage). After Cancidas was administered, patient had the following side effects: bacterial infection (What is bacterial infection?), organ failure. Cancidas dosage: . During the same period patient was treated with AMIKACIN (View Amikacin Review and Amikacin Label ), LINEZOLID (View Linezolid Review and Linezolid Label ), AMPHOTERICIN B AND L (ALPHA) DIMYRISTOYLPHOSPHATIDYLCHOLINE AND L (ALP (View Amphotericin B And L-(alpha)-dimyristoylphosphatidylcholine And L-(alp Review and Amphotericin B And L-(alpha)-dimyristoylphosphatidylcholine And L-(alp Label ), VORICONAZOLE (View Voriconazole Review and Voriconazole Label ).

6573817-5 | Chest Pain, Dyspnoea, Hypoxia, Myocardial Infarction, Tachycardia
Patient was taking Cancidas (View Usage). Patient experienced the following unwanted or unexpected effects: chest pain (What is chest pain?), dyspnoea, hypoxia, myocardial infarction, tachycardia on Feb 02, 2010 from UNITED KINGDOM Additional patient health information: Male patient , 74 years of age, weighting 132.3 lb, was diagnosed with bronchopulmonary aspergillosis allergic and. Cancidas dosage: . During the same period patient was treated with CEFTAZIDIME (View Ceftazidime Review and Ceftazidime Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ), ALBUTEROL (View Albuterol Review and Albuterol Label ). Patient was hospitalized.

6573804-7 | Gastrointestinal Anastomotic Leak, Large Intestine Perforation
Adverse event was reported on Feb 03, 2010 by a Female patient taking Cancidas (View Usage) (Dosage: ) was diagnosed with respiratory moniliasis, pneumonia (What is pneumonia?), bronchial carcinoma and. Location: GERMANY , 50 years of age, Patient had the following side effects: gastrointestinal anastomotic leak, large intestine perforation. During the same period patient was treated with MOXIFLOXACIN HYDROCHLORIDE (View Moxifloxacin Hydrochloride Review and Moxifloxacin Hydrochloride Label ), BEVACIZUMAB (View Bevacizumab Review and Bevacizumab Label ). Patient was hospitalized and became disabled.

6572485-6 | Cholestasis
on Jan 27, 2010 Male patient from FRANCE , 21 years of age, was diagnosed with candidiasis, staphylococcal sepsis, systemic candida, autism (What is autism?) and was treated with Cancidas (View Usage). After Cancidas was administered, patient had the following side effects: cholestasis. Cancidas dosage: . During the same period patient was treated with FLUCONAZOLE (View Fluconazole Review and Fluconazole Label ), RISPERIDONE (View Risperidone Review and Risperidone Label ), SERTRALINE HYDROCHLORIDE (View Sertraline Hydrochloride Review and Sertraline Hydrochloride Label ). Patient was hospitalized.

6568615-2 | Respiratory Failure
on Jan 25, 2010 Female patient from UNITED STATES , 14 years of age, was diagnosed with antifungal treatment, oral fungal infection and was treated with Cancidas (View Usage). Patient experienced the following unwanted or unexpected effects: respiratory failure. Cancidas dosage: . During the same period patient was treated with AMBISOME (View Ambisome Review and Ambisome Label ), POSACONAZOLE (View Posaconazole Review and Posaconazole Label ), VORICONAZOLE (View Voriconazole Review and Voriconazole Label ).

6556471-8 | Large Intestine Perforation
Patient was taking Cancidas (View Usage). Patient had the following side effects: large intestine perforation on Jan 25, 2010 from GERMANY Additional patient health information: Female patient , 50 years of age, was diagnosed with respiratory moniliasis and. Cancidas dosage: . During the same period patient was treated with MOXIFLOXACIN HYDROCHLORIDE (View Moxifloxacin Hydrochloride Review and Moxifloxacin Hydrochloride Label ).